UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

þ		ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2006

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

ADVENTRX PHARMACEUTICALS, INC.

Delaware		84-1318182
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
6725 Mesa Ridge Road, Suite 100 San Diego CA		92121
(Address of principal executive offices)		(Zip Code)

(858) 552-0866
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Name of each exchange on which registered:
Common Stock, par value $0.001 per share		The American Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o      No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o      No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statement incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o      Accelerated filer þ      Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO þ

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2006 was approximately $ 189,214,000, based upon the closing price on the American Stock Exchange reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. 89,676,739 shares of the registrant’s common stock were issued and outstanding as of March 12, 2007.

Not applicable.

 

 

EXPLANATORY NOTE

This amendment (“Amendment No. 2”) to the Annual Report on Form 10-K for the year ended December 31, 2006 of ADVENTRX Pharmaceuticals, Inc. (the “Company”), which was filed on March 15, 2007 (the “Annual Report”), is being filed for the sole purpose of amending Item 15 of Part IV of the Annual Report. Pursuant to Securities and Exchange Commission staff comments, the report of the independent registered public accounting firm (the “Report”) has been amended to exclude any reference to the report of the Company’s other auditors and the Company’s consolidated statements of operations, stockholders’ equity (deficit) and cash flows for the period from June 12, 1996 (date of inception) to December 31, 2001. The financial statements of the Company and subsidiaries (a development stage enterprise) to which the Report relates are not being amended or restated and appear in this Amendment No. 2 solely to comply with Rule 12b-15 under the Securities Exchange Act of 1934. Except for the changes to the Report described above, this Amendment No. 2 does not amend or update the Annual Report in any respect and, accordingly, this Amendment No. 2 should be read in conjunction with filings we have made with the Securities and Exchange Commission subsequent to March 15, 2007, the date of the original filing of the Annual Report.

Table of Contents

				Page
PART IV
Item 15.		Exhibits, Financial Statements and Schedules			1
		SIGNATURES			6
		EXHIBIT INDEX
EXHIBIT 23.1
EXHIBIT 31.1
EXHIBIT 31.2
EXHIBIT 32.1

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) Documents Filed. The following documents are filed as part of this report:

     (1) Financial Statements. The following report of J.H. Cohn LLP and financial statements:

	•		Report of J.H. Cohn LLP, Independent Registered Public Accounting Firm
	•		Consolidated Balance Sheets as of December 31, 2006 and 2005
	•		Consolidated Statements of Operations for the years ended December 31, 2006, 2005 and 2004 and from inception through December 31, 2006
	•		Consolidated Statements of Stockholders’ Equity (Deficit) from inception through December 31, 2006
	•		Consolidated Statements of Cash Flows for the years ended December 31, 2006, 2005 and 2004 and from inception through December 31, 2006
	•		Notes to Consolidated Financial Statements

     (2) Financial Statement Schedules. See subsection (c) below.

     (3) Exhibits. See subsection (b) below.

(b) Exhibits.

Exhibit		Description
2.1 (1)		Agreement and Plan of Merger, dated April 7, 2006, among the registrant, Speed Acquisition, Inc., SD Pharmaceuticals, Inc. and certain individuals named therein (including exhibits thereto)
3.1 (2)		Amended and Restated Certificate of Incorporation of the registrant
3.2 (3)		Amended and Restated Bylaws of the registrant (formerly known as Biokeys Pharmaceuticals, Inc.)
4.1(4)		Form of Registration Rights Agreement entered into in October and November 2001 (including the original schedule of holders)
4.2 (5)		$2.50 Warrant to Purchase Common Stock issued on April 12, 2002 to Emisphere Technologies, Inc.
4.3 (4)		Form of $0.60 Warrant to Purchase Common Stock issued May 28, 2003 (including the original schedule of holders)
4.4 (4)		Form of $1.25 Warrant to Purchase Common Stock issued between October 15, 2003 and December 29, 2003 (including the original schedule of holders)
4.5 (4)		Common Stock and Warrant Purchase Agreement, dated as of April 5, 2004, among the registrant and the Investors (as defined therein)
4.6 (4)		Registration Rights Agreement, dated April 5, 2004, among the registrant and the Investors (as defined therein)
4.7 (4)		Form of $2.00 A-1 Warrant to Purchase Common Stock issued April 8, 2004 (including the original schedule of holders)
4.8 (4)		Form of $2.50 A-2 Warrant to Purchase Common Stock issued April 8, 2004 (including the original schedule of holders)
4.9 (6)		Common Stock and Warrant Purchase Agreement, dated April 8, 2004, between the registrant and CD Investment Partners, Ltd.
4.10 (6)		Registration Rights Agreement, dated April 8, 2004, between the registrant and CD Investment Partners, Ltd.
4.11 (6)		$2.00 A-1 Warrant to Purchase Common Stock issued on April 8, 2004 to CD Investment Partners, Ltd.
4.12 (6)		$2.00 A-1 Warrant to Purchase Common Stock issued on April 8, 2004 to Burnham Hill Partners
4.13 (6)		$2.00 A-1 Warrant to Purchase Common Stock issued on April 8, 2004 to Ernest Pernet

Exhibit		Description
4.14 (6)		$2.00 A-1 Warrant to Purchase Common Stock issued on April 8, 2004 to W.R. Hambrecht + Co., LLC
4.15 (7)		Common Stock and Warrant Purchase Agreement, dated April 19, 2004, between the registrant and Franklin M. Berger
4.16 (8)		Registration Rights Agreement, dated April 19, 2004, between the registrant and Franklin M. Berger
4.17 (9)		$2.00 A-1 Warrant to Purchase Common Stock issued on April 19, 2004 to Franklin M. Berger
4.18 (8)		Securities Purchase Agreement, dated July 21, 2005, among the registrant and the Purchasers (as defined therein)
4.19 (8)		Rights Agreement, dated July 27, 2005, among the registrant, the Icahn Purchasers and Viking (each as defined therein)
4.20 (9)		First Amendment to Rights Agreement, dated September 22, 2006, among the registrant and the Icahn Purchasers (as defined therein)
4.21 (8)		Form of $2.26 Common Stock Warrant issued on July 27, 2005 (including the original schedule of holders)
4.22 (8)		Form of $2.26 Common Stock Warrant issued on July 27, 2005 (including the original schedule of holders)
4.23 (10)		$0.50 Warrant (WC-291) to Purchase Common Stock transferred on June 15, 2005 to S. Neborsky and R Neborsky TTEE Robert J. Neborsky MD Inc Comb Retirement Trust
4.24 (11)		$0.50 Warrant (WC-292) to Purchase Common Stock transferred on June 15, 2005 to S. Neborsky and R Neborsky TTEE Robert J. Neborsky MD Inc Comb Retirement Trust
4.25 (11)		$2.50 Warrant to Purchase Common Stock issued on October 22, 2004 to Thomas J. DePetrillo
10.1# (10)		2005 Equity Incentive Plan
10.2# (12)		Form of Stock Option Agreement under the 2005 Equity Incentive Plan
10.3# (2)		Form of Restricted Share Award Agreement under the 2005 Equity Incentive Plan
10.4# (12)		2005 Employee Stock Purchase Plan
10.5# (12)		Form of Subscription Agreement under the 2005 Employee Stock Purchase Plan
10.6* (13)		Option and License Agreement, dated January 23, 1998, between the registrant and the University of Southern California
10.7 (3)		First Amendment to License Agreement, dated August 16, 2000, between the registrant and the University of Southern California
10.8* (13)		Option and License Agreement, dated August 17, 2000, between the registrant and the University of Southern California

Exhibit		Description
10.9* (14)		Amendment to Option and License Agreement, dated April 21, 2003, between the registrant and the University of Southern California
10.10* (2)		Agreement, effective as of May 1, 2005, between the registrant and Pharm-Olam International Ltd.
10.11 (2)		Amendment dated July 19, 2005 to the Agreement between the registrant and Pharm-Olam International Ltd.
10.12 (15)		License Agreement, dated October 20, 2006, between the registrant, through its wholly-owned subsidiary SD Pharmaceuticals, Inc., and Theragenex, LLC
10.13 (10)		License Agreement, dated December 10, 2005, between SD Pharmaceuticals, Latitude Pharmaceuticals and Andrew Chen
10.14 (16)		Standard Multi-Tenant Office Lease — Gross, dated June 3, 2004, between the registrant and George V. Casey & Ellen M. Casey, Trustees of the Casey Family Trust dated June 22, 1998
10.15 (2)		First Amendment to the Standard Multi-Tenant Office Lease — Gross, dated June 3, 2004 between the registrant and George V. & Ellen M. Casey, Trustees of the Casey Family Trust dated June 22, 1998
10.16# (17)		Offer letter, dated March 5, 2003, to Joan M. Robbins
10.17# (18)		Offer letter, dated November 15, 2004, to Brian M. Culley
10.18# (18)		Offer letter, dated November 17, 2004, to Carrie Carlander
10.19# (19)		Severance Agreement and Release of All Claims, dated September 7, 2006, with Carrie Carlander
10.20# (19)		Consulting Agreement, dated September 7, 2006, with Carrie Carlander
10.21# (19)		Offer letter, dated September 7, 2006, to James A. Merritt
10.22# (19)		Form of Stock Option Agreement between the registrant and James A. Merritt (included in Exhibit 10.21)
10.23# (20)		Offer letter, dated December 13, 2006, to Gregory P. Hanson
10.24# (20)		Stock Option Agreement, effective December 20, 2006, between the registrant and Gregory P. Hanson
10.25 (21)		Form of Director and Officer Indemnification Agreement
10.26# (22)		Director compensation policy
10.27 (23)		Placement Agency Agreement, dated November 2, 2006, among the registrant, ThinkEquity Partners LLC and Fortis Securities LLC
14.1 (24)		Code of Business Conduct and Ethics
21.1 (10)		List of Subsidiaries
23.1		Consent of J.H. Cohn LLP, Independent Registered Public Accounting Firm
31.1		Certification of chief executive officer pursuant to Rule 13a-14(a)/15d-14(a)

Exhibit		Description
31.2		Certification of chief financial officer pursuant to Rule 13a-14(a)/15d-14(a)
32.1±		Certification of chief executive officer and chief financial officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 24, 2007

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature		Title		Date
/s/ Evan M. Levine   Evan M. Levine		Chief Executive Officer (Principal Executive Officer)		August 24, 2007
/s/ Gregory P. Hanson   Gregory P. Hanson		Chief Financial Officer, Senior Vice President, Finance, and Treasurer (Principal Financial and Accounting Officer)		August 24, 2007
*		Chairman of the Board
M. Ross Johnson
*		Director
Mark Bagnall
		Director
Alexander J. Denner
*		Director
Michael M. Goldberg
*		Director
Jack Lief
*		Director
Mark J. Pykett

* By:		/s/ Evan M. Levine   Evan M. Levine				August 24, 2007
		Attorney-in-Fact

Index to Consolidated Financial Statements

		Page
Report of Independent Registered Public Accounting Firm		F-2
Financial Statements:
Consolidated Balance Sheets		F-3
Consolidated Statements of Operations		F-4
Consolidated Statements of Stockholders’ Equity (Deficit)		F-5 - F-9
Consolidated Statements of Cash Flows		F-10 - F-11
Notes to Consolidated Financial Statements		F-12 - F-32
Financial Statement Schedules:
Financial statement schedules have been omitted for the reason that the required information is presented in financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders
ADVENTRX Pharmaceuticals, Inc.

We have audited the accompanying consolidated balance sheets of ADVENTRX Pharmaceuticals, Inc. and Subsidiaries (a development stage enterprise) as of December 31, 2006 and 2005, and the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2006 and for the period from January 1, 2002 to December 31, 2006. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of ADVENTRX Pharmaceuticals, Inc. and Subsidiaries (a development stage enterprise) as of December 31, 2006 and 2005, and the results of operations and their cash flows for each of the years in the three-year period ended December 31, 2006 and for the period from January 1, 2002 to December 31, 2006, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of ADVENTRX Pharmaceuticals, Inc. and Subsidiaries’ internal control over financial reporting as of December 31, 2006, based on criteria established in “Internal Control Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 23, 2007 expressed an unqualified opinion on management’s assessment of internal control over financial reporting and an unqualified opinion of the effectiveness of internal control over financial reporting.

/s/ J.H. Cohn LLP

San Diego, California
February 23, 2007

ADVENTRX Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Enterprise)

		December 31,
		2006				2005
Assets
Current assets:
Cash and cash equivalents		$	25,974,041			$	14,634,618
Short-term investments			25,771,406				7,958,458
Interest receivable			80,338				10,214
Prepaid expenses			511,327				255,802
Total current assets			52,337,112				22,859,092
Property and equipment, net			402,968				407,544
Other assets			58,305				355,137
Total assets		$	52,798,385			$	23,621,773
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable		$	480,402			$	593,228
Accrued liabilities			1,675,226				930,274
Accrued compensation and payroll taxes			292,896				173,398
Warrant liability			30,356,439				29,696,411
Total current liabilities			32,804,963				31,393,311
Long-term liabilities			35,674				57,078
Total liabilities			32,840,637				31,450,389
Commitments and contingencies
Temporary equity:
Common stock subject to continuing registration, $0.001 par value; 10,810,809 shares issued and outstanding			—				—
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized; 78,865,930 and 56,529,388 shares issued and outstanding at December 31, 2006 and 2005, respectively			89,678				67,364
Additional paid-in capital			109,166,773				52,105,329
Deficit accumulated during the development stage			(89,296,613	)			(59,964,840	)
Accumulated other comprehensive loss			(2,090	)			(1,722	)
Treasury stock, 23,165 shares at December 31, 2005, at cost			—				(34,747	)
Total stockholders’ equity (deficit)			19,957,748				(7,828,616	)
Total liabilities and stockholders’ equity (deficit)		$	52,798,385			$	23,621,773

See accompanying notes to consolidated financial statements.

ADVENTRX Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Enterprise)

														Inception
														(June 12, 1996)
														through
		Years Ended December 31,												December 31,
		2006				2005				2004				2006
Net sales		$	—			$	—			$	—			$	174,830
Cost of goods sold			—				—				—				51,094
Gross margin			—				—				—				123,736
Grant revenue			—				—				—				129,733
Total revenue			—				—				—				253,469
Operating expenses:
Research and development			12,001,212				8,682,498				2,744,328				28,157,964
In-process research and development			10,422,130				—				—				10,422,130
Selling, general and administrative			7,236,437				4,901,002				4,018,453				24,570,736
Depreciation and amortization			176,688				115,545				41,309				10,432,249
Impairment loss — write-off of goodwill			—				—				—				5,702,130
Equity in loss of investee			—				—				—				178,936
Total operating expenses			29,836,467				13,699,045				6,804,090				79,464,145
Loss from operations			(29,836,467	)			(13,699,045	)			(6,804,090	)			(79,210,676	)
Interest income			1,164,722				496,059				103,042				1,863,059
Loss on fair value of warrants			(660,028	)			(11,579,660	)			—				(12,239,688	)
Interest expense			—				—				—				(179,090	)
Loss before income taxes			(29,331,773	)			(24,782,646	)			(6,701,048	)			(89,766,395	)
Provision for income taxes			—				—				—				—
Loss before cumulative effect of change in accounting principle			(29,331,773	)			(24,782,646	)			(6,701,048	)			(89,766,395	)
Cumulative effect of change in accounting principle			—				—				—				(25,821	)
Net loss			(29,331,773	)			(24,782,646	)			(6,701,048	)			(89,792,216	)
Preferred stock dividends			—				—				—				(621,240	)
Net loss applicable to common stock		$	(29,331,773	)		$	(24,782,646	)		$	(6,701,048	)		$	(90,413,456	)
Loss per common share — basic and diluted		$	(0.40	)		$	(0.41	)		$	(0.13	)
Weighted average shares outstanding — basic and diluted			73,988,206				59,828,357				50,720,180

See accompanying notes to consolidated financial statements.

ADVENTRX Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Enterprise)

Inception (June 12, 1996) through December 31, 2006

																																										Deficit
																																						Accumulated				accumulated								Total
		Cumulative convertible								Cumulative convertible								Cumulative convertible																Additional				other				during the				Treasury				stockholders’
		preferred stock, series A								preferred stock, series B								preferred stock, series C								Common stock								paid-in				comprehensive				development				stock,				equity				Comprehensive
		Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				capital				loss				stage				at cost				(deficit)				loss
Balances at June 12, 1996 (date of incorporation)			—			$	—				—			$	—				—			$	—				—			$	—			$	—			$	—			$	—			$	—			$	—
Sale of common stock without par value			—				—				—				—				—				—				503				5				5				—				—				—				10
Change in par value of common stock			—				—				—				—				—				—				—				(4	)			4				—				—				—				—
Issuance of common stock and net liabilities assumed in acquisition			—				—				—				—				—				—				1,716,132				1,716				3,224				—				(18,094	)			—				(13,154	)
Issuance of common stock			—				—				—				—				—				—				2,010,111				2,010				456				—				(2,466	)			—				—
Net loss			—				—				—				—				—				—				—				—				—				—				(259,476	)			—				(259,476	)		$	(259,476	)
Balances at December 31, 1996			—				—				—				—				—				—				3,726,746				3,727				3,689				—				(280,036	)			—				(272,620	)		$	(259,476	)
Sale of common stock, net of offering costs of $9,976			—				—				—				—				—				—				1,004,554				1,004				1,789,975				—				—				—				1,790,979
Issuance of common stock in acquisition			—				—				—				—				—				—				375,891				376				887,874				—				—				—				888,250
Minority interest deficiency at acquisition charged to the Company			—				—				—				—				—				—				—				—				—				—				(45,003	)			—				(45,003	)
Net loss			—				—				—				—				—				—				—				—				—				—				(1,979,400	)			—				(1,979,400	)		$	(1,979,400	)
Balances at December 31, 1997			—				—				—				—				—				—				5,107,191				5,107				2,681,538				—				(2,304,439	)			—				382,206			$	(1,979,400	)
Rescission of acquisition			—				—				—				—				—				—				(375,891	)			(376	)			(887,874	)			—				561,166				—				(327,084	)
Issuance of common stock at conversion of notes payable			—				—				—				—				—				—				450,264				451				363,549				—				—				—				364,000
Expense related to stock warrants issued			—				—				—				—				—				—				—				—				260,000				—				—				—				260,000
Net loss			—				—				—				—				—				—				—				—				—				—				(1,204,380	)			—				(1,204,380	)		$	(1,204,380	)
Balances at December 31, 1998			—				—				—				—				—				—				5,181,564				5,182				2,417,213				—				(2,947,653	)			—				(525,258	)		$	(1,204,380	)
Sale of common stock			—				—				—				—				—				—				678,412				678				134,322				—				—				—				135,000
Expense related to stock warrants issued			—				—				—				—				—				—				—				—				212,000				—				—				—				212,000
Net loss			—				—				—				—				—				—				—				—				—				—				(1,055,485	)			—				(1,055,485	)		$	(1,055,485	)
Balances at December 31, 1999			—				—				—				—				—				—				5,859,976				5,860				2,763,535				—				(4,003,138	)			—				(1,233,743	)		$	(1,055,485	)
Sale of preferred stock, net of offering costs of $76,500			3,200				32				—				—				—				—				—				—				3,123,468				—				—				—				3,123,500

See accompanying notes to consolidated financial statements.

																																										Deficit
																																						Accumulated				accumulated								Total
		Cumulative convertible								Cumulative convertible								Cumulative convertible																Additional				other				during the				Treasury				stockholders’
		preferred stock, series A								preferred stock, series B								preferred stock, series C								Common stock								paid-in				comprehensive				development				stock,				equity				Comprehensive
		Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				capital				loss				stage				at cost				(deficit)				loss
Issuance of common stock at conversion of notes and interest payable			—				—				—				—				—				—				412,487				412				492,085				—				—				—				492,497
Issuance of common stock at conversion of notes payable			—				—				—				—				—				—				70,354				70				83,930				—				—				—				84,000
Issuance of common stock to settle obligations			—				—				—				—				—				—				495,111				496				1,201,664				—				—				—				1,202,160
Issuance of common stock for acquisition			—				—				—				—				—				—				6,999,990				7,000				9,325,769				—				—				—				9,332,769
Issuance of warrants for acquisition			—				—				—				—				—				—				—				—				4,767,664				—				—				—				4,767,664
Stock issued for acquisition costs			—				—				—				—				—				—				150,000				150				487,350				—				—				—				487,500
Expense related to stock warrants issued			—				—				—				—				—				—				—				—				140,000				—				—				—				140,000
Dividends payable on preferred stock			—				—				—				—				—				—				—				—				(85,000	)			—				—				—				(85,000	)
Cashless exercise of warrants			—				—				—				—				—				—				599,066				599				(599	)			—				—				—				—
Net loss			—				—				—				—				—				—				—				—				—				—				(3,701,084	)			—				(3,701,084	)		$	(3,701,084	)
Balances at December 31, 2000			3,200				32				—				—				—				—				14,586,984				14,587				22,299,866				—				(7,704,222	)			—				14,610,263			$	(3,701,084	)
Dividends payable on preferred stock			—				—				—				—				—				—				—				—				(256,000	)			—				—				—				(256,000	)
Repurchase of warrants			—				—				—				—				—				—				—				—				(55,279	)			—				—				—				(55,279	)
Sale of warrants			—				—				—				—				—				—				—				—				47,741				—				—				—				47,741
Cashless exercise of warrants			—				—				—				—				—				—				218,493				219				(219	)			—				—				—				—
Issuance of common stock to pay preferred dividends			—				—				—				—				—				—				93,421				93				212,907				—				—				—				213,000
Detachable warrants issued with notes payable			—				—				—				—				—				—				—				—				450,000				—				—				—				450,000
Issuance of warrants to pay operating expenses			—				—				—				—				—				—				—				—				167,138				—				—				—				167,138
Issuance of common stock to pay operating expenses			—				—				—				—				—				—				106,293				106				387,165				—				—				—				387,271
Issuance of preferred stock to pay operating expenses			137				1				—				—				—				—				—				—				136,499				—				—				—				136,500
Net loss			—				—				—				—				—				—				—				—				—				—				(16,339,120	)			—				(16,339,120	)		$	(16,399,120	)
Balances at December 31, 2001			3,337				33				—				—				—				—				15,005,191				15,005				23,389,818				—				(24,043,342	)			—				(638,486	)		$	(16,399,120	)
Dividends payable on preferred stock			—				—				—				—				—				—				—				—				(242,400	)			—				—				—				(242,400	)
Repurchase of warrants			—				—				—				—				—				—				—				—				—				—				—				—				—
Sale of warrants			—				—				—				—				—				—				240,000				240				117,613				—				—				—				117,853
Cashless exercise of warrants			—				—				—				—				—				—				100,201				100				(100	)			—				—				—				—

See accompanying notes to consolidated financial statements.

																																										Deficit
																																						Accumulated				accumulated								Total
		Cumulative convertible								Cumulative convertible								Cumulative convertible																Additional				other				during the				Treasury				stockholders’
		preferred stock, series A								preferred stock, series B								preferred stock, series C								Common stock								paid-in				comprehensive				development				stock,				equity				Comprehensive
		Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				capital				loss				stage				at cost				(deficit)				loss
Exercise of warrants			—				—				—				—				—				—				344,573				345				168,477				—				—				—				168,822
Sale of preferred stock at $1.50 per share			—				—				200,000				2,000				—				—				—				—				298,000				—				—				—				300,000
Sale of preferred stock at $10.00 per share			—				—				—				—				70,109				701				—				—				700,392				—				—				—				701,093
Conversion of preferred stock into common stock			(3,000	)			(30	)			—				—				—				—				1,800,000				1,800				(1,770	)			—				—				—				—
Preferred stock dividends forgiven			—				—				—				—				—				—				—				—				335,440				—				—				—				335,440
Issuance of warrants to pay operating expenses			—				—				—				—				—				—				—				—				163,109				—				—				—				163,109
Issuance of common stock to pay operating expenses			—				—				—				—				—				—				6,292				6				12,263				—				—				—				12,269
Issuance of preferred stock to pay operating expenses			136				1				—				—				—				—				—				—				6,000				—				—				—				6,001
Issuance of stock options to employees			—				—				—				—				—				—				—				—				329,296				—				—				—				329,296
Net loss			—				—				—				—				—				—				—				—				—				—				(2,105,727	)			—				(2,105,727	)		$	(2,105,727	)
Balances at December 31, 2002			473				4				200,000				2,000				70,109				701				17,496,257				17,496				25,276,138				—				(26,149,069	)			—				(852,730	)		$	(2,105,727	)
Dividends payable on preferred stock			—				—				—				—				—				—				—				—				(37,840	)			—				—				—				(37,840	)
Conversion of Series C preferred stock into common stock			—				—				—				—				(70,109	)			(701	)			14,021,860				14,022				(13,321	)			—				—				—				—
Issuance of common stock to pay interest on Bridge Notes			—				—				—				—				—				—				165,830				165				53,326				—				—				—				53,491
Sale of common stock at $0.40 per share, net of issuance costs			—				—				—				—				—				—				6,640,737				6,676				2,590,656				—				—				—				2,597,332
Sale of common stock at $1.00 per share, net of issuance costs			—				—				—				—				—				—				3,701,733				3,668				3,989,181				—				—				—				3,992,849
Exchange of warrants			—				—				—				—				—				—				235,291				235				49,486				—				—				—				49,721
Issuance of common stock to pay operating expenses			—				—				—				—				—				—				230,000				230				206,569				—				—				—				206,799
Issuance of warrants to pay operating expenses			—				—				—				—				—				—				—				—				156,735				—				—				—				156,735
Issuance of stock options to employees			—				—				—				—				—				—				—				—				286,033				—				—				—				286,033
Net loss			—				—				—				—				—				—				—				—				—				—				(2,332,077	)			—				(2,332,077	)		$	(2,332,077	)
Balances at December 31, 2003			473				4				200,000				2,000				—				—				42,491,708				42,492				32,556,963				—				(28,481,146	)			—				4,120,313			$	(2,332,077	)